Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies

Presentations to include data from IV-administered programs in genetic epilepsy due to STXBP1 mutations and Parkinson’s disease with GBA mutations THOUSAND OAKS, Calif., Sept. 4, 2024 /PRNewswire/ — Capsida Biotherapeutics (“Capsida”), a leading fully integrated targeted gene therapy…